What guidance did ADC Therapeutics's management provide for the next earnings period?

What factors drove the changes in ADC Therapeutics's revenue and profit?

What were the key takeaways from ADC Therapeutics’s earnings call?

What is the revenue and EPS growth rate for ADC Therapeutics year over year?

Did ADC Therapeutics beat or miss consensus estimates last quarter?

What is ADC Therapeutics's gross profit margin?

What is ADC Therapeutics's latest dividend and current dividend yield?

What were the key takeaways from ADC Therapeutics's earnings call?

- **Stable ZYNLONTA revenue**: $15.8M Q3 2025, maintaining third-line DLBCL market position.
- **Pipeline momentum**: LOTIS-5 Phase III data H1 2026, LOTIS-7 interim update Q4 2025 with 93.3% ORR.
- **Peak revenue vision**: $600-1B U.S. for ZYNLONTA, driven by second-line DLBCL ($200-300M) and MZL ($100-200M).
- **Financial strength**: $292M cash post-PIPE, 2028+ runway, 12% YoY expense reduction.

**【CEO Summary Section】**
- Q3 2025 net product revenues: $15.8 million (down 12.2% YoY), reflecting stable demand for ZYNLONTA in third-line DLBCL.
- Key pipeline updates:
  - LOTIS-5 Phase III: Top-line data expected H1 2026; targeting $200-300M peak revenue in second-line DLBCL.
  - LOTIS-7 Phase Ib: 93.3% ORR, 86.7% CR in 30 evaluable pts; interim update with 6+ months follow-up planned Q4 2025.
- Peak revenue potential: $600-1B in U.S. for ZYNLONTA across DLBCL and indolent lymphomas.
- $60M private placement extends cash runway to 2028.

**【CFO Financial Commentary】**
- Q3 2025 financials:
  - GAAP net loss: $41M (vs. $44M YoY)
  - Non-GAAP operating expenses: $45M (12.1% YoY decline)
  - Cash balance: $234.7M (pre PIPE) → $292.3M post $60M financing.
- R&D efficiency: $15M reduction in expenses vs. 2024.
- Upcoming catalysts: LOTIS-5 data H1 2026, LOTIS-7 regulatory engagement 2026.

**【Q&A Highlights】**
- LOTIS-7 enrollment: Accelerated post-June data; targeting 100 pts but may complete sooner.
- Revenue ramp timing: Regulatory approvals/compendia listings expected H1 2027, with 2-year ramp-up.
- Frontline DLBCL strategy: Monitoring bispecifics; no plans for standalone Phase III.
- Sales force strategy: Balanced approach for complex (academic) vs. broad-access (community) settings.
- Indolent lymphoma potential: MZL ($100-200M peak) > FL due to lower competition and higher CR rates (70% vs. 30%).

ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

ADCT

ADCT fundamentals

You can ask Aime